U.S., June 24 -- ClinicalTrials.gov registry received information related to the study (NCT07032298) titled 'A Phase I Study of SSGJ-612 in Patients With Advanced Solid Tumors' on June 19.
Brief Summary: This study is an open-label phase I study to evaluate the safety, pharmacokinetics, and antitumor activity of SSGJ-612 in patients with advanced malignant solid tumors expressing HER2.
Study Start Date: July, 2025
Study Type: INTERVENTIONAL
Condition:
Advanced Malignant Tumors
Intervention:
DRUG: SSGJ-612
Intravenous injection
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Shenyang Sunshine Pharmaceutical Co., LTD.
Published by HT Digital Content Services with permission from Health Daily Digest....